Neuronal alpha-6-containing nicotinic acetylcholine receptor (alpha6* nAChR)

Neuronal alpha-6-containing nicotinic acetylcholine receptors (alpha6* nAChRs) are pentameric ligand-gated ion channels that are highly localized within the catecholaminergic pathways of the central nervous system, particularly in the substantia nigra and ventral tegmental area (UniProt: P43681). These receptors are unique because they specifically regulate the release of dopamine in the striatum, a process vital for motor coordination and reward processing (PMID: 15140637). In Parkinson's disease, alpha6* nAChRs are among the first to be lost, suggesting they are sensitive markers and potential therapeutic targets for neuroprotection (PMID: 21835177). They also play a pivotal role in the reinforcing effects of nicotine, making them targets for smoking cessation and addiction therapies (PMID: 17202403). Pharmacological targeting of these receptors often involves selective peptides like alpha-conotoxin MII or small molecules like BPiDI, though achieving selectivity over other nicotinic subtypes remains a primary hurdle (PubChem: CID 11870434).

Other names

CHRNA6Cholinergic receptor nicotinic alpha 6 subunitAlpha-6 nicotinic receptornACHRA6Neuronal acetylcholine receptor subunit alpha-6

Ligand-gated ion channel activation or inhibition; drugs act as agonists, partial agonists, or antagonists to modulate the flow of cations (Na+, K+, Ca2+) across the neuronal membrane, thereby regulating neurotransmitter release, particularly dopamine (PMID: 15140637).